DiaMedica Therapeutics (DMAC) Capital Expenditures (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Capital Expenditures for 9 consecutive years, with $3000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures fell 50.0% year-over-year to $3000.0; the trailing twelve-month figure through Jun 2026 stood at $33000.0 (down 2.94% YoY), and the FY2025 full-year result was $40000.0, up 60.0% from the prior year.
• Capital Expenditures retreated to $3000.0 in Q2 2026 per DMAC's latest filing, from $8000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $43000.0 in Q3 2022 and bottomed at $3000.0 in Q4 2023.
• Historically, Capital Expenditures has averaged $11312.5 across 5 years, with a median of $7500.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures jumped 2050.0% in 2022, then slumped 90.62% in 2023.
• Over 5 years, Capital Expenditures stood at $32000.0 in 2022, then plunged by 90.62% to $3000.0 in 2023, then surged by 133.33% to $7000.0 in 2024, then dropped by 14.29% to $6000.0 in 2025, then plunged by 50.0% to $3000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $3000.0, $8000.0, and $6000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.